Great progress has been made over the past 10-20 years in characterizing B-cell lymphoproliferative diseases, particularly CLL. Immunophenotypic analysis, as well as molecular genetics, has significantly contributed to this characterization. However, significant heterogeneity still exists in the clinical courses of patients diagnosed with this disease. Further progress in defining subsets of patients with a more homogenous prognosis will likely be aided by further identification of molecular aberrations in this disease.

0 0

Post a comment